Sep 18, 2023 · Discover cutting-edge treatments for tardive syndrome. Learn about FDA-approved meds, personalized approaches, and future perspectives in one place.

Mar 24, 2025 · Jump To TD-Specific Meds New Antipsychotics Brain Stimulation Outlook It can be scary when you or a loved one has been diagnosed with tardive dyskinesia (TD), a disorder characterized …

Tardive dyskinesia (TD) is a heterogeneous, hyperkinetic movement disorder induced by dopamine-receptor blocking agents that presents a unique challenge in the treatment of psychosis. Although …

Mar 20, 2025 · Check out new data from the long-term, open-label KINECT 4 study on Ingrezza capsules for the treatment of tardive dyskinesia.

Nov 4, 2025 · Tardive dyskinesia (TD) is no longer an unavoidable side-effect waiting to happen. Once viewed as a largely intractable consequence of long-term dopamine-blocking antipsychotics, this …

Jul 14, 2025 · Medications for Parkinsonism worsen tardive dyskinesia symptoms, and vice versa. Only 2 FDA-approved medications for tardive dyskinesia sit on the market—tetrabenazine and …

Mar 20, 2025 · The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, …

Dec 2, 2025 · The findings demonstrate that treatment with AUSTEDO (deutetrabenazine) tablets or AUSTEDO XR (deutetrabenazine) extended-release tablets for tardive dyskinesia (TD) led to …

Mar 21, 2025 · New data reveals 48-week remission in tardive dyskinesia treatment with Ingrezza valbenazine capsules.

Sep 20, 2025 · AUSTEDO XR (deutetrabenazine) extended-release tablets and AUSTEDO (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with …